Eroom's Law: The Declining ROI of Drug Discovery Explained

Eroom's Law is a term coined by researchers to describe the trend of declining returns on investment (ROIs) in the field of drug discovery. The name 'Eroom's Law' is derived from the phrase 'Moore's Law' (which describes the exponential growth of computing power over time) spelled backward.

Eroom's Law suggests that despite advancements in technology and scientific knowledge, the number of new drugs being discovered and approved by regulatory authorities is decreasing while the costs of drug development are increasing. In other words, the productivity of the pharmaceutical industry in terms of discovering new drugs is declining.

This phenomenon can be attributed to various factors such as the increasing complexity of diseases, higher regulatory standards, longer development timelines, and rising costs associated with clinical trials. As a result, pharmaceutical companies are facing challenges in generating sufficient revenue from new drug discoveries to offset the increasing costs of research and development.

The increasing demand for new drugs, coupled with declining drug discovery ROIs, highlights the need for innovative approaches, such as artificial intelligence and machine learning, to accelerate the drug discovery process and improve its efficiency.